Lauren Biscaldi is the Managing Editor of Drug Topics.
Slideshow: 2023 Biologic Product Approvals
Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.
Slideshow: 2023 Biosimilar Approvals
In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.
Slideshow: 2023 Vaccine Approvals
Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.
CDC: Vaccine Coverage for Respiratory Viruses Needs to Increase
Immunizations against influenza, COVID-19, and RSV are lower than they were this time last year, and hospitalizations have increased across all age groups.
Evaluating Multiple Myeloma Survival Rates by Race, Ethnicity, and Rural-Urban Location
Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.
Understanding Adverse Events With BCMA-, Non-BCMA-Targeting Bispecific Antibodies in Multiple Myeloma
Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.
Daratumumab Plus VRd Improves Progression Free Survival in Newly Diagnosed Multiple Myeloma
Results of the phase 3 PERSEUS study were presented at the 2023 ASH Annual Meeting and Exposition.
Mitigating Financial Toxicity for Patients and Providers
Safiya Tisdell, vice president of Adparo Services at Annexus Health, details the available assistance options designed to ease the financial burden associated with accessing care for both patients and providers.
Education Around Importance of Medication Monitoring Procedures Key at a Long-Term Care Psychiatric Facility
Increased clinical awareness around the value of lithium monitoring was ultimately achieved.
Adalimumab-atto Biosimilar Well Received After Launch
Most patients were not concerned about losing control over their disease after switching.
Rural Patients Utilize ED for Migraine at Higher Rates
These populations are also more likely to receive opioid analgesic therapies.
The Unintended Impact of Opioid Prescribing Guidelines: Part 1
The CDC first released opioid prescribing guidelines in 2016.
Slideshow: Evaluating Perioperative Opioid Use and Analgesic Options
Three poster presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative pain management.
Navigating the Oncology Specialty Patient Journey
In a conversation from this year's Healthcare Advocate Summit, Randy Falkenrath demystified the oncology medication management model and explained how specialty pharmacist can help patients access care.
Zonisamide Clinical Update and Literature Review
Zonisamide has a role in the treatment of epilepsy and is being explored in other central nervous system disorders.
AHA: Semaglutide Significantly Reduces MACE in Adults With Overweight or Obesity, CVD
Data demonstrated a 20% risk reduction for major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
First OTC Rapid Antigen Test for COVID-19 Cleared By FDA
The test is also the first OTC rapid antigen test cleared for any infectious disease.
FDA Approves First Licensed Chikungunya Virus Vaccine
Ixchiq was approved through the FDA Accelerated Approval pathway.
Expert Interview: Protein-Based Vaccines for COVID-19
Vaccine manufacturers, including Novavax, are still hard at work updating immunizations against a mutating SARS-CoV-2 virus.
Breaking: FDA Approves Tirzepatide Injection for Chronic Weight Management in Obesity, Overweight
The drug, Zepbound, will be available in the United States by the end of 2023.
Ustekinumab-auub Approved as First Interchangeable Biosimilar to Stelara
Ustekinumab-auub is approved for use in both adult and pediatric populations.
FDA Approves Penbraya Vaccine to Prevent Against Meningococcal A, B, C, W, and Y
In the Opioid Epidemic, Treatment Challenges Still Persist
Despite societal need, stigma around MAT and MOUD still exists.
Preparation, Cooperation Key to Successfully Navigate DEA Audits and Investigations
An ounce of prevention is well worth a pound of cure when it comes to DEA investigations.
Oral Etrasimod Approved for Moderately to Severely Active Ulcerative Colitis
Approval was based on favorable data from two ELEVATE UC phase 3 clinical trials.
University of South Carolina Team Wins 2023 Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition
The winner was announced during the 2023 NCPA Annual Convention and Expo.
Rethinking STI Testing Through Partnerships Between Community Pharmacy and Public Health
Community pharmacists and their colleagues in the public health space can work together to increase STI testing and treatment in at-risk groups.
Register Today: October 2023 Total Pharmacy Solutions Summit
Conference Preview: NCPA 2023 Annual Convention and Expo
This year’s meeting will take place from October 14–17 in Orlando, Florida.
Telehealth Model, CGM Use Supports T1D, T2D Self-Management
There has been growing evidence around the potential for the success of remote diabetes care and CGM technology use.